Genmab — Oktober 2018

nohope

#MeToo

jkj

US spurter forsat flot op, NBI taber dog pusten lidt, så verdens mest magtfulde mand fik alligevel ødelagt festen inden rigtig kom igang

Helge_LarsenPI-redaktør

Just a moment...

(www.proinvestor.com)

jkj

Dax fut. falder over 1 % Putin truer europa i missilstrid.

jkj

Jesus

JKY_VH

har han kigget for dybt i vodkaflasken?

transalp

Det næste bliver vel at han 'will build a wall'... hvordan mon vi er havnet her, med to historieløse idioter...

jkj

Det passer fint pensionisten, kursen lukker med et plus på 1.03 futten viser lige nu plus 0,5, det vil betyde -0,53 imorgen lige nu.

jkj

DAX Futures | Xetra DAX Futures - Investing.com

Live DAX futures prices & pre-market data including DAX futures charts, news, analysis & more DAX futures coverage.

Investing.com (www.investing.com)

jkj

dax fut. viser åbning på -2,4 % jeg kan ikke finde nyheder der skulle understøtte dette, men det kræves vel hellere ikke i dette marked.

jkj

Det er tilsyneladende dårlige end ventet resultater fra Alphabet og Amazon, der spreder skræk efter US børsluk.

Solsen

Måske er det blot fordi det er fredag.

Plimsoller

God morgen

Helge_LarsenPI-redaktør

God morgen.

Plimsoller

Så er smileyen tilbage hos Helge. Det lover godt for dagens marked

Plimsoller

E_L

from Seattle Genetics earnings report:

E_L

Tisotumab Vedotin (TV) Program Highlights
•Phase 1/2 Data Presented at ESMO: Seattle Genetics and Genmabreported updated data from the cervical cancer expansion cohort of theinnovaTV 201 phase 1/2 trial at the European Society for MedicalOncology 2018 Congress. The data continue to support the rationale forthe ongoing potentially pivotal trial, innovaTV 204, evaluating TV asmonotherapy for patients with recurrent and/or metastatic cervicalcancer who have relapsed or progressed after standard of

E_L

of caretreatment.
•InnovaTV 208 Phase 2 trial in Ovarian Cancer: Seattle Geneticsand Genmab plan to evaluate the safety and activity of TV asmonotherapy in patients with platinum-resistant ovarian cancer. Thetrial is expected to begin by early 2019.

E_L

from Earnings Conference Call Transcript: https://www.fool.com/earnings/call-transcripts/2018/10/26/seattle-genetics-inc-sgen-q3-2018-earnings-confere.aspx